Albumedix Limited

Novozymes Biopharma Dk A/s

Novozymes Biopharma Dic A/s

Albumedix A/s

Jason Cameron

Jan Terje Andersen

Andrew Plumridge

Esben Peter Friis

Darrell Sleep

Inger Sandlie

Karen Ann Delahay

Jens Erik Nielsen

David James Ballance

John Rodney Woodrow

Stephen Berezenko

Hendrik Van Urk

Philip Harvey Morton

Andrew John Cartwright

Jean-Luc Bernard Veron

Steven James Burton

Christopher John Arthur Finnis

David John Mead

Joanna Mary Hay

Phillip Harvey Morton

Richard Anthony Dodd

Mark Jonathan Burton

Steven Athwal

Michael Gaston Joseph Grandgeorge

Elizabeth Allan

Bjorn Dalhus

Michel Gaston Joseph Grandgeorge

Leslie Evans

Lee Edward Blackwell

Malcolm John Saxton

Neil Dodsworth

Joanna Hay

Miranda Hughes

Gurdeep Singh Athwal

Leslie Robert Evans

Joanne Patricia Waters

David John Tooth

Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as 'thio-albumin'). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.

Albumin variants and conjugates

The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Albumin variants

The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.

Albumin derivatives and variants

An improved method for purifying albumin, a variant or fragment thereof, a fusion protein comprising albumin, a variant or fragment thereof, or a conjugate comprising albumin, a variant or fragment thereof is disclosed.

Method for purifying albumin

A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons. Also disclosed is a process for producing recombinant albumin, the process comprising culturing a fungal cell expressing a is recombinant albumin coding sequence, wherein the cell has a reduced capacity of mannosylation of the recombinantly-expressed albumin.

Process for the purification of recombinant albumin

Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.

A process is provided for the preparation of a highly pure recombinant albumin solution having a nickel ion content of less than 100 ng per gram of albumin. The process comprises subjecting a recombinant albumin to a series of chromatography, concentration, and diafiltration steps.

Growing community of inventors

Nottingham, United Kingdom

Jason Cameron